{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T21:53:39Z","timestamp":1790978019525,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1016\/j.leukres.2011.12.002","type":"journal-article","created":{"date-parts":[[2011,12,31]],"date-time":"2011-12-31T09:33:26Z","timestamp":1325324006000},"page":"756-763","source":"Crossref","is-referenced-by-count":31,"title":["Potentiation of Nilotinib-mediated cell death in the context of the bone marrow microenvironment requires a promiscuous JAK inhibitor in CML"],"prefix":"10.1016","volume":"36","author":[{"given":"Rajesh R.","family":"Nair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel H.","family":"Tolentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul F.","family":"Argilagos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Pinilla-Ibarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori A.","family":"Hazlehurst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2011.12.002_bib0005","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.2408149","article-title":"Tyrosine kinase activity and transformation potency of bcr-abl oncogene products","volume":"247","author":"Lugo","year":"1990","journal-title":"Science (New York, NY)"},{"key":"10.1016\/j.leukres.2011.12.002_bib0010","first-page":"6","article-title":"Evaluating the effect of P210 BCR\/ABL on growth of hematopoietic progenitor cells and its role in the pathogenesis of human chronic myelogenous leukemia","volume":"30","author":"Gishizky","year":"1993","journal-title":"Seminars in Hematology"},{"key":"10.1016\/j.leukres.2011.12.002_bib0015","doi-asserted-by":"crossref","first-page":"e7439","DOI":"10.1371\/journal.pone.0007439","article-title":"A BCR-ABL mutant lacking direct binding sites for the GRB2, CBL and CRKL adapter proteins fails to induce leukemia in mice","volume":"4","author":"Johnson","year":"2009","journal-title":"PloS One"},{"key":"10.1016\/j.leukres.2011.12.002_bib0020","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2011.12.002_bib0025","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1002\/cncr.24504","article-title":"Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R)","volume":"115","author":"Kantarjian","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2011.12.002_bib0030","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.leukres.2011.12.002_bib0035","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.leukres.2011.12.002_bib0040","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S1470-2045(11)70201-7","article-title":"Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial","volume":"12","author":"Kantarjian","year":"2011","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.leukres.2011.12.002_bib0045","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1038\/leu.2010.185","article-title":"Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR","volume":"24","author":"Ross","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2011.12.002_bib0050","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1182\/blood-2002-09-2780","article-title":"Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment","volume":"101","author":"Bhatia","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.12.002_bib0055","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1182\/blood-2004-04-1335","article-title":"Discontinuation of imatinib therapy after achieving a molecular response","volume":"104","author":"Cortes","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.12.002_bib0060","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","article-title":"Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years","volume":"109","author":"Rousselot","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.12.002_bib0065","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI35721","article-title":"Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity","volume":"121","author":"Corbin","year":"2011","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.leukres.2011.12.002_bib0070","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1038\/sj.leu.2402179","article-title":"Cell adhesion-mediated drug resistance (CAM-DR) protects the K562 chronic myelogenous leukemia cell line from apoptosis induced by BCR\/ABL inhibition, cytotoxic drugs, and gamma-irradiation","volume":"15","author":"Damiano","year":"2001","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2011.12.002_bib0075","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/leu.2009.299","article-title":"Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors","volume":"24","author":"Hiwase","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2011.12.002_bib0080","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1158\/1535-7163.MCT-08-0314","article-title":"Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance","volume":"7","author":"Bewry","year":"2008","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1016\/j.leukres.2011.12.002_bib0085","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/S0301-472X(02)00812-3","article-title":"Isolation of bone marrow mesenchymal stem cells by anti-nerve growth factor receptor antibodies","volume":"30","author":"Quirici","year":"2002","journal-title":"Experimental Hematology"},{"key":"10.1016\/j.leukres.2011.12.002_bib0090","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1158\/1535-7163.MCT-09-0113","article-title":"HYD1-induced increase in reactive oxygen species leads to autophagy and necrotic cell death in multiple myeloma cells","volume":"8","author":"Nair","year":"2009","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1016\/j.leukres.2011.12.002_bib0095","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1182\/blood-2004-02-0749","article-title":"Identification of mcl-1 as a BCR\/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides","volume":"105","author":"Aichberger","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.12.002_bib0100","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1182\/blood-2002-03-0844","article-title":"Gene expression profiling of the functionally distinct human bone marrow stromal cell lines HS-5 and HS-27a","volume":"100","author":"Graf","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.12.002_bib0105","doi-asserted-by":"crossref","DOI":"10.1177\/0091270010389469","article-title":"The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers","author":"Shi","year":"2011","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1016\/j.leukres.2011.12.002_bib0110","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis","volume":"363","author":"Verstovsek","year":"2010","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.leukres.2011.12.002_bib0115","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nature02067","article-title":"Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1","volume":"426","author":"Opferman","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2011.12.002_bib0120","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/leu.2008.364","article-title":"The stem cell factor-c-KIT pathway must be inhibited to enable apoptosis induced by BCR-ABL inhibitors in chronic myelogenous leukemia cells","volume":"23","author":"Belloc","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2011.12.002_bib0125","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1182\/blood-2003-04-1271","article-title":"BCR\/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells","volume":"103","author":"Chu","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.12.002_bib0130","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/sj.leu.2405086","article-title":"Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors","volume":"22","author":"Konig","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2011.12.002_bib0135","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1182\/blood.V99.10.3792","article-title":"Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation","volume":"99","author":"Holtz","year":"2002","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212611005807?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212611005807?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,27]],"date-time":"2018-11-27T05:28:01Z","timestamp":1543296481000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212611005807"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["S0145212611005807"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2011.12.002","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]}}}